Latest Interim Results News

Tryptamine Therapeutics has reported successful Phase 1b results for its IV-infused psilocin candidate TRP-8803 and promising interim data for oral psilocybin TRP-8802 in IBS treatment, while securing $6 million in new funding to accelerate clinical development.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.

Terrain Minerals reports encouraging early drilling results at its Wildflower Gold Project, progresses metallurgical studies at Larins Lane Gallium Project, and initiates nickel-copper drilling at Lort River, backed by a $450,000 strategic placement.

SelfWealth Limited reported a modest revenue increase for the half-year ended December 2024, yet profits plunged sharply due to higher operating expenses as the company prepares for a potential acquisition by Bell Financial Group.

Visioneering Technologies reports promising interim results from its PROTECT trial, showing significant control of myopia progression in children using NaturalVue® Multifocal lenses.

Myer reports flat comparable sales and a slight dip in total sales for the 22 weeks to December 2024, while reaffirming support for its transformative merger with Premier Investments' Apparel Brands.